SAMI Pharmaceuticals Pvt. Ltd.
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi-based pharmaceutical manufacturer and marketer of branded generic medicines across major therapeutic categories.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- SAMI Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 34-C, Block-6, P.E.C.H.S., Karachi-75350, Pakistan · 75350
- Website
- samipharma.com ↗
- Phone
- +92 21 34527490-92
- samiho@samikhi.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| ACTIM | Bisoprolol fumarate | 5 mg | Tablet | 14's | 034068 | PKR 190.83 | PKR 13.63/tablet | 16% above median |
| ACTIM | Bisoprolol fumarate | 10 mg | Tablet | 1x28's | 034069 | PKR 619.75 | PKR 22.13/tablet | Near median |
| ACTIM | Bisoprolol fumarate | 10 mg | Tablet | 14's | 034069 | PKR 316.20 | PKR 22.59/tablet | Near median |
| ACTIM | Bisoprolol fumarate | 2.5 mg | Tablet | 3x10's | 045362 | PKR 140.03 | PKR 4.67/tablet | 10% above median |
| ACTIM | Bisoprolol fumarate | 2.5 mg | Tablet | 20's | 045362 | PKR 93.35 | PKR 4.67/tablet | 10% above median |
| ANTIAL | Loratadine | 10 mg | Tablet | 20's | 019675 | PKR 610.47 | PKR 30.52/tablet | 113% above median |
| ANTIAL | Loratadine | 10 mg | Tablet | 10's | 019675 | PKR 311.46 | PKR 31.15/tablet | 117% above median |
| ANTIAL | Loratadine | 5 mg/5 mL | Oral solution | 30ml | 019878 | PKR 87.88 | PKR 2.93/mL | 101% above median |
| Arcenate | Artesunate | 30 mg | Injection | 1's | 100927 | PKR 148.71 | PKR 148.71/vial/unit | Near median |
| Arcenate | Artesunate | 60 mg | Injection | 1's | 100928 | PKR 247.84 | PKR 247.84/vial/unit | Near median |
| Arcenate | Artesunate | 120 mg | Injection | 1's | 100929 | PKR 413.07 | PKR 413.07/vial/unit | Near median |
| ARCEVA | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 053225 | PKR 660.92 | PKR 41.31/tablet | 5% above median |
| ARCEVA | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8's | 053226 | PKR 545.26 | PKR 68.16/tablet | 6% above median |
| ARCEVA | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6's | 058381 | PKR 681.55 | PKR 113.59/tablet | Near median |
| ARCEVA | Artemether | 80 mg/mL | Injection | 6 x 1 ml | 085601 | PKR 1,239.23 | PKR 206.54/mL | 11% above median |
| ARCEVA | Artemether | 80 mg/mL | Injection | 5 x 1 ml | 085601 | PKR 977.38 | PKR 195.48/mL | Near median |
| ARCEVA 20 | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 053225 | PKR 660.92 | PKR 41.31/tablet | 5% above median |
| ARILIO | Tacrolimus | 0.5 mg | Capsule | 30's | 097116 | PKR 1,886.76 | PKR 62.89/capsule | 10% above median |
| ARILIO | Tacrolimus | 0.5 mg | Capsule | 10's | 097116 | PKR 683.61 | PKR 68.36/capsule | 20% above median |
| ARILIO | Tacrolimus | 5 mg | Capsule | 10's | 098710 | PKR 5,696.75 | PKR 569.68/capsule | 12% above median |
| ARILIO | Tacrolimus | 1 mg | Capsule | 50's | 098711 | PKR 5,240.99 | PKR 104.82/capsule | 8% above median |
| ARILIO | Tacrolimus | 1 mg | Capsule | 10's | 098711 | PKR 1,139.33 | PKR 113.93/capsule | 17% above median |
| ARILIO | Tacrolimus | 1 mg | Capsule | 30's | 098711 | PKR 3,144.62 | PKR 104.82/capsule | 8% above median |
| ARNEZA | Anastrozole | 1 mg | Tablet | 30's | 096211 | PKR 11,400.27 | PKR 380.01/tablet | 11% above median |
| AZITMA | Azithromycin | 250 mg | Tablet | 6's | 074899 | PKR 314.07 | PKR 52.35/tablet | 12% above median |
| AZITMA | Azithromycin | 250 mg | Tablet | 12's | 074899 | PKR 615.58 | PKR 51.30/tablet | 9% above median |
| AZITMA | Azithromycin | 500 mg | Tablet | 6's | 074900 | PKR 575.83 | PKR 95.97/tablet | 13% above median |
| AZITMA | Azithromycin | 200 mg/5 mL | Suspension | 30ml | 074902 | PKR 677.57 | PKR 22.59/mL | Near median |
| AZITMA | Azithromycin | 200 mg/5 mL | Suspension | 15ml | 074902 | PKR 345.48 | PKR 23.03/mL | 6% above median |
| BELIC | Entecavir | 1 mg | Tablet | 30's | 085603 | PKR 22,237.81 | PKR 741.26/tablet | 28% above median |
| BELIC | Entecavir | 0.05 mg/mL | Oral solution | 120ml | 088232 | PKR 5,186.31 | PKR 43.22/mL | Near median |
| BISLERI | Iron polymaltose complex + Folic acid | 100 mg + 350 mcg | Capsule | 30'S | 029394 | PKR 503.25 | PKR 16.78/capsule | No comparator |
| Bisleri | Iron polymaltose complex + Folic acid | 100 mg + 350 mcg | Tablet | 10's | 029394 | PKR 174.75 | PKR 17.48/tablet | 18% above median |
| BISLERI | Iron polymaltose complex + Folic acid | 100 mg elemental iron + 350 mcg folic acid | Chewable tablet | 10's | 029396 | PKR 183.77 | PKR 18.38/tablet | 23% above median |
| BISLERI | Iron polymaltose complex + Folic acid | 100 mg + 350 mcg | Chewable tablet | 30'S | 029396 | PKR 529.22 | PKR 17.64/tablet | No comparator |
| BREEKY | Misoprostol | 200 mcg | Tablet | 10's | 073698 | PKR 209.39 | PKR 20.94/tablet | Near median |
| BRINO | Tranexamic acid | 250 mg/5 mL | Injection | 10's | 039503 | PKR 945.93 | PKR 94.59/vial/unit | 55% above median |
| BRINO | Tranexamic acid | 500 mg/5 mL | Injection | 10's | 044062 | PKR 1,755.55 | PKR 175.56/vial/unit | 16% above median |
| Caffcit | Caffeine citrate | 20 mg/mL | Solution for infusion / Oral solution | 1mlx1's | 135218 | PKR 3,251.00 | PKR 3,251.00/mL | No comparator |
| CARICEF | Cefixime | 100 mg/5 mL | Suspension | 60 ml | 022415 | PKR 408.93 | PKR 6.82/mL | 35% below median |
| CARICEF | Cefixime | 100 mg/5 mL | Suspension | 30 ml | 022415 | PKR 365.33 | PKR 12.18/mL | 16% above median |
| CARICEF | Cefixime | 400 mg | Capsule | 5's | 022416 | PKR 654.67 | PKR 130.93/capsule | 16% above median |
| CARICEF | Cefixime | 200 mg/5 mL | Suspension | 30 ml | 044340 | PKR 447.08 | PKR 14.90/mL | 12% above median |
| CARICEF | Cefixime | 200 mg | Tablet | 10's | 070790 | PKR 648.51 | PKR 64.85/tablet | Near median |
| CERN-C | Ascorbic acid | 500 mg | Tablet | 4x10's | 114675 | PKR 80.22 | PKR 2.01/tablet | 55% above median |
| Cynfo | Fosfomycin | 1 g | Powder for IV infusion | 1's | 089069 | PKR 82.16 | PKR 82.16/vial/unit | No comparator |
| Cynfo | Fosfomycin | 1 g | Solution for infusion | 1's | 089069 | PKR 82.16 | PKR 82.16/vial/unit | No comparator |
| D-TRES | Cholecalciferol | 5 mg/mL | Injection | 1's | 076115 | PKR 283.27 | PKR 283.27/vial/unit | 30% above median |
| D-TRES | Cholecalciferol | 5 mg | Injection | 5's | 076115 | PKR 1,241.88 | PKR 248.38/vial/unit | 29% above median |
| D-TRES | Cholecalciferol | 5 mg | Injection | 1's | 076115 | PKR 283.27 | PKR 283.27/vial/unit | 47% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.